Novavax, Inc. (NVAX)
| Market Cap | 1.64B |
| Revenue (ttm) | 1.29B |
| Net Income (ttm) | -1.48B |
| Shares Out | 78.22M |
| EPS (ttm) | -17.51 |
| PE Ratio | n/a |
| Forward PE | 0.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,273,361 |
| Open | 21.84 |
| Previous Close | 22.44 |
| Day's Range | 20.46 - 22.37 |
| 52-Week Range | 20.46 - 249.04 |
| Beta | 1.64 |
| Analysts | Buy |
| Price Target | 124.03 (+490.6%) |
| Earnings Date | Nov 2, 2022 |
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate... [Read more...]
Financial Performance
In 2021, Novavax's revenue was $1.15 billion, an increase of 141.02% compared to the previous year's $475.60 million. Losses were -$1.74 billion, 316.9% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is 124.03, which is an increase of 490.62% from the latest price.
News
Why Novavax (NVAX) Stock Was Down 13% on Thursday
Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.
Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On? - Moderna (NASDAQ:MRNA)
Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.
Novavax stock dives after JPMorgan downgrades shares
This segment originally aired on September 22, 2022. Yahoo Finance Live's Julie Hyman discusses Novavax stock performance after JPMorgan downgrades its shares to Underweight from Neutral.
Why Novavax Stock Is Plunging This Week
Novavax has some serious short-term challenges but could still have growth opportunities in the future.
Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak
Novavax stock is trading at a two-year low amid slowly ramping use of its Covid vaccine, dubbed Nuvaxovid, in the U.S. The post Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak appeared f...
Why Novavax Stock Hit a Fresh 52-Week Low Today
The biotech's shares are crumbling today following an analyst downgrade.
Novavax stock extends plunge after J.P. Morgan turns bearish, on expectations of more guidance cuts
Shares of Novavax Inc. NVAX, -7.46% slumped 7.1% in morning trading Thursday, to extend their recent plunge toward a near 2 1/2-year low, after J.P. Morgan threw in the towel on the maker of the COVID-1...
Why Is Novavax (NVAX) Stock Falling Today?
Novavax (NASDAQ: NVAX ) stock fell 6% on Sept. 21, and kept falling overnight, after a JP Morgan Chase analyst cut his price target from over $100/share down to just $27 with an “underperform” rating.
Vaccine Stocks Down After Biden Says Pandemic is Over
BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vaccine Stocks: Down but Not Out?
Whether the pandemic is over or not, plenty of people are still looking for protection against COVID-19.
Why Novavax and Johnson & Johnson Stocks Slipped Today
The latest pronouncements by the president aren't exactly doing the two healthcare companies any favors.
Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?
It's a mixed day for the stock market, but it's not a good day for vaccine stocks. Across the board, these names are getting sold.
Moderna, BioNTech, and Novavax plunge after President Biden says the COVID-19 pandemic 'is over'
"The pandemic is over. We still have a problem with COVID. We're still doing a low of work on it. But the pandemic is over," Biden said.
Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is over
Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with "60 Minutes" that aired on Sunday. Moderna Inc. MRNA, -9.41% fell 9....
Why BioNTech, Moderna And Novavax Shares Are Diving
BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo
Novavax says its COVID vaccine is now available in Israel for use in people aged 12 and older
Novavax Inc. NVAX, said Friday that Israel has granted an import and use permit for the company's COVID vaccine for use in people aged 12 and older. The vaccine is protein based, using a more traditiona...
Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Ag...
GAITHERSBURG, Md. , Sept. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious disea...
Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older
The Israeli Advisory Committee on Epidemics has recommended that Nuvaxovid™ be approved for ages 12 and older as a primary series and as a heterologous booster for those previously vaccinated with mRNA ...
Novavax (NVAX) Flat As Market Sinks: What You Should Know
Novavax (NVAX) closed the most recent trading day at $32.55, making no change from the previous trading session.
Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults
Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.
Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine a...
GAITHERSBURG, Md. , Sept. 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious disea...
Novavax's COVID-19 booster is now authorized in Europe
Shares of Novavax Inc. NVAX, +1.83% were up 2.4% in trading on Monday after the company said its COVID-19 booster has been authorized in Europe for adults. Novavax's stock has declined 77.3% so far this...
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Us...
Nuvaxovid™ is now authorized in the EU for use in adults aged 18 and older as a booster regardless of previous vaccine history GAITHERSBURG, Md. , Sept. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: N...
3 Stocks Expecting Good News From the FDA
Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.